The Dutch biopharmaceuticals firm Pharming NV reports a 48% rise to 18.5million euros ($17.1 million) in its revenues for 2000 and says that operating expenses increased 32% to 35.1 million euros, resulting in an increased loss of 18% to 16.6 million euros. However, at the same time Pharming notes that its cash burn has been limited to 7.8 million euros for the year, compared with 18.6 million euros in 1999. At the end of 2000, the company had cash available of 44.9 million euros.
Pharming's president and chief executive, George Hersbach, has said that he is positive about 2001, noting that "our strong focus on clinical development and manufacturing of our biopharmaceutical products will allow us to take major steps toward regulatory market authorization of our first products."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze